Role of memantine in adult migraine: a systematic review and network meta-analysis to compare memantine with existing migraine preventive medications
Guanglu Li, Baoquan Qu, Tao Zheng, Shaojie Duan, Lei Liu, Zunjing Liu · 2024
Read Role of memantine in adult migraine: a systematic review and network meta-analysis to compare memantine with existing migraine preventive medications by Guanglu Li, Baoquan Qu, Tao Zheng, Shaojie Duan, Lei Liu, Zunjing Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11688350.txt.
Description
Guanglu Li and five co-authors ask whether an Alzheimer's drug borrowed for migraine beats the standard preventives. Their 2024 network meta-analysis gathers thirty-eight randomized trials with over thirteen thousand patients, and ranks memantine against guideline-backed options through the web of indirect comparisons. The main measures were change in migraine days, the share of patients at least halving their attacks, and dropout from side effects.
Memantine posted the second-largest cut in migraine days and the highest halving rate, fifty percent responders, of any treatment studied, alongside the lowest dropout. The authors are quick to caveat: its confidence intervals still crossed no-effect, few trials compared it head-to-head, and long-term data are missing, so the shine may be partly optimism. Their verdict is prioritization, not triumph: memantine deserves a serious place in prevention choices, prescribed with conservative judgment.
Catalog record
| CREATOR | Guanglu Li, Baoquan Qu, Tao Zheng, Shaojie Duan, Lei Liu, Zunjing Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |